Header and Body 2

Problem Addressed

The role of CDN as an immunomodulatory compound has been demonstrated for a while; however, its use has been limited due to poor pharmacokinetics. Injected CDN is rapidly flushed from the site of injection, leading to systemic inflammation. Thus, there is a need for CDN delivery methods that retain the compound at the site of injection. The current invention utilizes synthetic nanoparticles formed by mixing CDN with peptide nucleic acid (PNA)-amphiphile conjugate to increase retention at the site of injection and avoid systemic inflammatory effects.